TARS Stock Forecast: Tarsus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$73
−6.00% on the day

The 10 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +42.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 72 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$3.8B
Ticker Nerd rank
72/ 100
Median analyst target
$104
Analysts covering
10
Revenue$173.9M+69.4% y/y
Operating income−$19.9M
Net income−$18.6M
Free cash flow$57.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.1%
1M
+2.8%
YTD
−10.8%
1Y
−5.2%
From 52W high
−19.6%
From 52W low
+30.1%
$56
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tarsus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
72/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Accruals
95
Volatility
95
Quality
82
Momentum
72
Growth
45
Revisions
35
Issuance
22

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TARS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TARS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26TARSHigh $116Median $104Low $88

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10
Buy
0
Hold
0
Sell
$88
Low
$104
Median
$116
High

The green dot is the last close — the median target sits +42.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
5 Nov 2026GuggenheimMaintainsBuy$89 → $97
4 Nov 2026HC Wainwright & Co.MaintainsBuy$88 → $106
24 Sept 2026Goldman SachsReinstatesBuy$116
16 Sept 2026BarclaysReinstatesOverweight$110
8 Sept 2026JefferiesMaintainsBuy$88 → $105
12 Aug 2026OppenheimerMaintainsOutperform$97 → $100
31 July 2026MizuhoMaintainsOutperform$100 → $98
21 July 2026GuggenheimMaintainsBuy$90 → $89
9 July 2026HC Wainwright & Co.ReiteratesBuy$88
4 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026GuggenheimMaintainsBuy—
25 Feb 2026OppenheimerMaintainsOutperform—
9 Dec 2025BarclaysInitiatesOverweight—
20 Nov 2025MizuhoInitiatesOutperform—
5 Nov 2025GuggenheimMaintainsBuy—
20 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 May 2025HC Wainwright & Co.AssumesBuy$72
5 May 2025Goldman SachsMaintainsNeutral—
2 May 2025GuggenheimMaintainsBuy—
6 Mar 2025JefferiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TARS.

Market Radar

This page is one stock. Monday covers all of them.

TARS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TARS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tarsus Pharmaceuticals, Inc. returned −5.2% against +6.9% for the S&P 500, dividends included.

TARS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26TARSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TARS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
5.4×

Cheaper than 20% of US stocks

Price / book
35.4×

Cheaper than 2% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
93.0%

Higher than 97% of US stocks

Operating margin
−9.6%

Higher than 26% of US stocks

Net margin
—
Returns & dividend
Return on equity
−319.8%

Higher than 4% of US stocks

Return on assets
−7.9%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tarsus Pharmaceuticals, Inc. has a market value of $3.8B and an enterprise value of $3.6B.

  • Revenue in the twelve months to 30 June 2026: $606.3M. The latest quarter grew 69.4% year on year.

  • Net income over the same four quarters: −$46.5M, a −7.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.09.

  • Free cash flow in the twelve months to 30 June 2026: $56.0M.

  • Shares outstanding: 43.3M.

  • forward P/E: 347.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tarsus Pharmaceuticals, Inc. employs 370 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TARS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TARSTarsus Pharmaceuticals, Inc.$3.8B72
TNGXTango Therapeutics, Inc.$3.5B23
XENEXenon Pharmaceuticals, Inc.$3.5B41
RLAYRelay Therapeutics, Inc.$3.5B80
CRSPCRISPR Therapeutics AG$3.8B33
PBLSParabilis Medicines, Inc.$3.4B2
DFTXDefinium Therapeutics, Inc.$3.9B50

Take a look at TARS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tarsus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TARS

What is the TARS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $88 to $116. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TARS stock a buy right now?

Of the 10 analysts covering Tarsus Pharmaceuticals, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tarsus Pharmaceuticals, Inc. 72 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TARS?

As at 21 Nov 2026, Tarsus Pharmaceuticals, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will TARS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +42.4% from the last close, and Ticker Nerd's factor model ranks Tarsus Pharmaceuticals, Inc. 72 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TARS stock forecast for 2030?

No analyst covering Tarsus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $88 to $116 over the next 12 months.

How has TARS stock performed over the past year?

Tarsus Pharmaceuticals, Inc. returned -5.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tarsus Pharmaceuticals, Inc. do?

Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites.

Company

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites. Tarsus Pharmaceuticals also advances additional ophthalmology assets and supports a broader eye-care franchise aimed at treating unmet needs in outpatient and specialist settings. Its business combines drug development, regulatory execution, and commercial distribution, making it an important participant in the ophthalmology and specialty pharmaceuticals market. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc. concentrates on transforming proven science into targeted treatments for patients and eye-care providers.

CEO Dr. Bobak R. Azamian M.D. · 370 employees · United States · https://tarsusrx.com